IQV IQVIA | $197.57
+1.6% | 11/19/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $260.00 -> $248.00 | N/A | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 11/19/2024 |
RCKT Rocket Pharmaceuticals | $13.00
-0.3% | 11/19/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $46.00 -> $44.00 | N/A | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/19/2024 |
EHAB Enhabit | $7.41
-0.7% | 11/19/2024 | Reiterated by | Leerink Partners | - | Market Perform -> Market Perform | $8.50 -> $8.00 | N/A | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 11/19/2024 |
ICLR ICON Public | $212.76
+4.5% | 11/19/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $270.00 -> $255.00 | N/A | View details for Leerink Partners rating of ICON Public (NASDAQ:ICLR) on 11/19/2024 |
ACRS Aclaris Therapeutics | $4.32
+9.1% | 11/19/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $2.00 -> $7.00 | N/A | View details for Leerink Partners rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/19/2024 |
CMPX Compass Therapeutics | $1.38
+0.7% | 11/15/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $5.00 -> $4.00 | N/A | View details for Leerink Partners rating of Compass Therapeutics (NASDAQ:CMPX) on 11/15/2024 |
|
LXEO Lexeo Therapeutics | $6.20
+1.3% | 11/13/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $20.00 -> $19.00 | N/A | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/13/2024 |
MASS 908 Devices | $2.74
+7.0% | 11/13/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $12.00 -> $4.00 | N/A | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 11/13/2024 |
ARDT Ardent Health Partners | $15.85
-3.6% | 11/12/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $23.00 -> $25.00 | N/A | View details for Leerink Partners rating of Ardent Health Partners (NYSE:ARDT) on 11/12/2024 |
NGNE Neurogene | $15.59
+1.7% | 11/12/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $45.00 -> $72.00 | N/A | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 11/12/2024 |
BMY Bristol-Myers Squibb | $58.22
+0.6% | 11/12/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $55.00 -> $73.00 | N/A | View details for Leerink Partners rating of Bristol-Myers Squibb (NYSE:BMY) on 11/12/2024 |
TECX Tectonic Therapeutic | $44.89
+2.0% | 11/11/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $49.00 -> $69.00 | N/A | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 11/11/2024 |
XRAY DENTSPLY SIRONA | $18.64
+0.6% | 11/7/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | N/A | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 11/7/2024 |
ZYME Zymeworks | $13.70
-5.8% | 11/7/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $10.00 -> $25.00 | N/A | View details for Leerink Partners rating of Zymeworks (NYSE:ZYME) on 11/7/2024 |
BEAM Beam Therapeutics | $23.52
-4.0% | 11/6/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $27.00 -> $39.00 | N/A | View details for Leerink Partners rating of Beam Therapeutics (NASDAQ:BEAM) on 11/6/2024 |
IDYA IDEAYA Biosciences | $26.60
+4.2% | 11/5/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $41.00 -> $27.00 | Low | View details for Leerink Partners rating of IDEAYA Biosciences (NASDAQ:IDYA) on 11/5/2024 |
ZURA Zura Bio | $2.93
+1.0% | 11/4/2024 | Initiated by | Leerink Partners | - | Outperform | $15.00 | High | View details for Leerink Partners rating of Zura Bio (NASDAQ:ZURA) on 11/4/2024 |
NVST Envista | $21.39
+5.0% | 10/31/2024 | Upgraded by | Leerink Partners | - | Underperform -> Market Perform | $16.00 -> $23.00 | High | View details for Leerink Partners rating of Envista (NYSE:NVST) on 10/31/2024 |
AQST Aquestive Therapeutics | $4.56
-3.8% | 10/25/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $12.00 -> $13.00 | Low | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 10/25/2024 |
DXCM DexCom | $74.48
-1.0% | 10/25/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $90.00 -> $87.00 | High | View details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/25/2024 |
ICLR ICON Public | $212.76
+4.5% | 10/25/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $376.00 -> $270.00 | High | View details for Leerink Partners rating of ICON Public (NASDAQ:ICLR) on 10/25/2024 |
TENX Tenax Therapeutics | $4.85
+1.7% | 10/24/2024 | Initiated by | Leerink Partners | - | Outperform | $16.00 | High | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 10/24/2024 |
GILD Gilead Sciences | $89.84
+1.4% | 10/21/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $74.00 -> $96.00 | Low | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 10/21/2024 |
TNYA Tenaya Therapeutics | $2.16
-2.7% | 10/18/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | | Low | View details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 10/18/2024 |
AMLX Amylyx Pharmaceuticals | $5.24
| 10/18/2024 | Target Set by | Leerink Partners | Analyst Marc Goodman | Market Perform -> Market Perform | $4.00 | High | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 10/18/2024 |
LXRX Lexicon Pharmaceuticals | $0.78
-3.7% | 10/18/2024 | Target Set by | Leerink Partners | Analyst Roanna Ruiz | Outperform -> Outperform | $6.00 | Low | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 10/18/2024 |
ISRG Intuitive Surgical | $550.43
+1.6% | 10/17/2024 | Target Raised by | Leerink Partners | - | | $489.00 -> $502.00 | Low | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/17/2024 |
BBIO BridgeBio Pharma | $23.24
+0.9% | 10/17/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $47.00 -> $46.00 | Low | View details for Leerink Partners rating of BridgeBio Pharma (NASDAQ:BBIO) on 10/17/2024 |
MIRM Mirum Pharmaceuticals | $43.48
-0.5% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $47.00 -> $49.00 | Low | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 10/17/2024 |
ILMN Illumina | $137.09
+4.1% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $160.00 -> $200.00 | Low | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 10/17/2024 |
MASS 908 Devices | $2.74
+7.0% | 10/17/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $15.00 -> $12.00 | Medium | View details for Leerink Partners rating of 908 Devices (NASDAQ:MASS) on 10/17/2024 |
NTRA Natera | $169.20
+0.8% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $140.00 -> $150.00 | Medium | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 10/17/2024 |
RVTY Revvity | $111.11
-0.2% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $130.00 -> $135.00 | Low | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 10/17/2024 |
TWST Twist Bioscience | $41.89
+1.9% | 10/17/2024 | Target Raised by | Leerink Partners | - | Market Perform -> Market Perform | $45.00 -> $48.00 | Medium | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 10/17/2024 |
VCYT Veracyte | $38.94
-0.7% | 10/17/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $35.00 -> $40.00 | Low | View details for Leerink Partners rating of Veracyte (NASDAQ:VCYT) on 10/17/2024 |
GH Guardant Health | $31.09
+1.3% | 10/17/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $60.00 -> $50.00 | High | View details for Leerink Partners rating of Guardant Health (NASDAQ:GH) on 10/17/2024 |
WVE Wave Life Sciences | $14.35
+0.6% | 10/16/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $20.00 -> $22.00 | High | View details for Leerink Partners rating of Wave Life Sciences (NASDAQ:WVE) on 10/16/2024 |
VYGR Voyager Therapeutics | $5.43
+1.3% | 10/16/2024 | Initiated by | Leerink Partners | - | Outperform | $15.00 | High | View details for Leerink Partners rating of Voyager Therapeutics (NASDAQ:VYGR) on 10/16/2024 |
MNMD Mind Medicine (MindMed) | $7.04
-6.4% | 10/14/2024 | Initiated by | Leerink Partners | - | Outperform | $20.00 | High | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 10/14/2024 |
STOK Stoke Therapeutics | $11.37
+0.5% | 10/14/2024 | Initiated by | Leerink Partners | - | Outperform | $18.00 | High | View details for Leerink Partners rating of Stoke Therapeutics (NASDAQ:STOK) on 10/14/2024 |
Central Bank Abandons USD (Ad) You know what doesn't care about elections? Gold.
If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!
 Get Your FREE Gold Investor Kit NOW! |
HOLX Hologic | $78.68
+0.8% | 10/8/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $95.00 -> $90.00 | Low | View details for Leerink Partners rating of Hologic (NASDAQ:HOLX) on 10/8/2024 |
TVTX Travere Therapeutics | $18.41
+3.1% | 10/8/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $20.00 -> $20.00 | Medium | View details for Leerink Partners rating of Travere Therapeutics (NASDAQ:TVTX) on 10/8/2024 |
COR Cencora | $245.50
+0.9% | 10/7/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $277.00 -> $275.00 | Low | View details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2024 |
MCK McKesson | $628.15
+1.1% | 10/7/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $665.00 -> $630.00 | Low | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2024 |
HUM Humana | $296.39
+0.8% | 10/2/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $400.00 -> $250.00 | High | View details for Leerink Partners rating of Humana (NYSE:HUM) on 10/2/2024 |
AQST Aquestive Therapeutics | $4.56
-3.8% | 9/30/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $10.00 -> $12.00 | High | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 9/30/2024 |
AGIO Agios Pharmaceuticals | $55.54
+1.7% | 9/27/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $60.00 -> $56.00 | High | View details for Leerink Partners rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 9/27/2024 |
REGN Regeneron Pharmaceuticals | $745.48
+0.3% | 9/24/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $1,175.00 -> $1,077.00 | High | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 9/24/2024 |
BHVN Biohaven | $45.19
-3.5% | 9/23/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $55.00 -> $60.00 | Low | View details for Leerink Partners rating of Biohaven (NYSE:BHVN) on 9/23/2024 |
SPRY ARS Pharmaceuticals | $13.42
-1.0% | 9/20/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $21.00 -> $25.00 | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/20/2024 |
APLT Applied Therapeutics | $9.32
-1.2% | 9/19/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $11.00 -> $14.00 | Low | View details for Leerink Partners rating of Applied Therapeutics (NASDAQ:APLT) on 9/19/2024 |
FDMT 4D Molecular Therapeutics | $7.99
-5.0% | 9/19/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $40.00 -> $36.00 | High | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 9/19/2024 |
PGNY Progyny | $14.97
+7.1% | 9/19/2024 | Target Lowered by | Leerink Partners | - | Market Perform -> Market Perform | $25.00 -> $21.00 | High | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 9/19/2024 |
ICLR ICON Public | $212.76
+4.5% | 9/18/2024 | Initiated by | Leerink Partners | - | Outperform | $379.00 | High | View details for Leerink Partners rating of ICON Public (NASDAQ:ICLR) on 9/18/2024 |
MRNA Moderna | $38.40
+4.0% | 9/17/2024 | Target Lowered by | Leerink Partners | - | Underperform -> Underperform | $60.00 -> $48.00 | Medium | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 9/17/2024 |
ORKA Oruka Therapeutics | $20.50
-7.7% | 9/17/2024 | Initiated by | Leerink Partners | - | Outperform | $44.00 | Low | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/17/2024 |
FULC Fulcrum Therapeutics | $2.97
-0.7% | 9/12/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $4.00 | N/A | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 9/12/2024 |
INSP Inspire Medical Systems | $186.19
+0.8% | 9/10/2024 | Target Raised by | Leerink Partners | - | Market Perform -> Market Perform | $167.00 -> $197.00 | Low | View details for Leerink Partners rating of Inspire Medical Systems (NYSE:INSP) on 9/10/2024 |
MNKD MannKind | $6.90
+0.3% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $7.00 -> $8.00 | Medium | View details for Leerink Partners rating of MannKind (NASDAQ:MNKD) on 9/9/2024 |
PLRX Pliant Therapeutics | $12.85
+0.9% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $46.00 -> $33.00 | Low | View details for Leerink Partners rating of Pliant Therapeutics (NASDAQ:PLRX) on 9/9/2024 |
PRTC PureTech Health | $21.78
+0.4% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $58.00 -> $45.00 | High | View details for Leerink Partners rating of PureTech Health (NASDAQ:PRTC) on 9/9/2024 |
TRVI Trevi Therapeutics | $2.73
-1.4% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $6.00 -> $7.00 | High | View details for Leerink Partners rating of Trevi Therapeutics (NASDAQ:TRVI) on 9/9/2024 |
IMUX Immunic | $1.12
+3.7% | 9/9/2024 | Reiterated by | Leerink Partners | - | Outperform | $5.00 | Low | View details for Leerink Partners rating of Immunic (NASDAQ:IMUX) on 9/9/2024 |
KYMR Kymera Therapeutics | $44.11
+0.1% | 9/9/2024 | Reiterated by | Leerink Partners | - | Outperform | $60.00 | Medium | View details for Leerink Partners rating of Kymera Therapeutics (NASDAQ:KYMR) on 9/9/2024 |
IRWD Ironwood Pharmaceuticals | $3.34
-5.1% | 9/9/2024 | Initiated by | Leerink Partners | - | Market Perform | $5.00 | High | View details for Leerink Partners rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) on 9/9/2024 |
GLPG Galapagos | $25.17
-1.8% | 9/9/2024 | Initiated by | Leerink Partners | - | Market Perform | $24.00 | High | View details for Leerink Partners rating of Galapagos (NASDAQ:GLPG) on 9/9/2024 |
GERN Geron | $4.02
+0.8% | 9/9/2024 | Initiated by | Leerink Partners | - | Outperform | $7.00 | Medium | View details for Leerink Partners rating of Geron (NASDAQ:GERN) on 9/9/2024 |
MCK McKesson | $628.15
+1.1% | 9/5/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $670.00 -> $665.00 | Low | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 9/5/2024 |
PCVX Vaxcyte | $88.39
+2.8% | 9/3/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $106.00 -> $153.00 | Low | View details for Leerink Partners rating of Vaxcyte (NASDAQ:PCVX) on 9/3/2024 |
RXRX Recursion Pharmaceuticals | $5.79
-4.1% | 9/3/2024 | Target Lowered by | Leerink Partners | - | Market Perform -> Market Perform | $9.00 -> $8.00 | Low | View details for Leerink Partners rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 9/3/2024 |
NARI Inari Medical | $49.80
+1.6% | 9/3/2024 | Initiated by | Leerink Partners | - | Market Perform | $47.00 | Low | View details for Leerink Partners rating of Inari Medical (NASDAQ:NARI) on 9/3/2024 |
PEN Penumbra | $240.15
+0.4% | 9/3/2024 | Initiated by | Leerink Partners | - | Outperform | $263.00 | Low | View details for Leerink Partners rating of Penumbra (NYSE:PEN) on 9/3/2024 |
TXG 10x Genomics | $13.38
+0.5% | 9/3/2024 | Initiated by | Leerink Partners | - | Outperform | $35.00 | Low | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/3/2024 |
SPRY ARS Pharmaceuticals | $13.42
-1.0% | 8/12/2024 | Target Raised by | Leerink Partners | - | Outperform | $19.00 -> $20.00 | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 8/12/2024 |
ARDT Ardent Health Partners | $15.85
-3.6% | 8/12/2024 | Initiated by | Leerink Partners | - | Outperform | $23.00 | Low | View details for Leerink Partners rating of Ardent Health Partners (NYSE:ARDT) on 8/12/2024 |
ARCT Arcturus Therapeutics | $17.06
+5.5% | 8/12/2024 | Initiated by | Leerink Partners | - | Outperform | $70.00 | Low | View details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/12/2024 |
PGNY Progyny | $14.97
+7.1% | 8/7/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $31.00 -> $25.00 | Low | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 8/7/2024 |
TBPH Theravance Biopharma | $9.61
-3.6% | 8/6/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $15.00 -> $10.00 | Low | View details for Leerink Partners rating of Theravance Biopharma (NASDAQ:TBPH) on 8/6/2024 |
RCM R1 RCM | $14.31
| 8/1/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $17.00 -> $14.30 | Low | View details for Leerink Partners rating of R1 RCM (NASDAQ:RCM) on 8/1/2024 |
WAT Waters | $368.00
+2.9% | 8/1/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $325.00 -> $375.00 | Low | View details for Leerink Partners rating of Waters (NYSE:WAT) on 8/1/2024 |
TECX Tectonic Therapeutic | $44.89
+2.0% | 7/24/2024 | Initiated by | Leerink Partners | - | Outperform | $49.00 | Low | View details for Leerink Partners rating of Tectonic Therapeutic (NASDAQ:TECX) on 7/24/2024 |
DHR Danaher | $234.76
+0.7% | 7/24/2024 | Target Raised by | Leerink Partners | - | Outperform | $275.00 -> $280.00 | Low | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 7/24/2024 |
HCA HCA Healthcare | $332.22
-0.2% | 7/24/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $367.00 -> $396.00 | Low | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 7/24/2024 |
IONS Ionis Pharmaceuticals | $33.83
-4.4% | 7/24/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $53.00 -> $62.00 | Low | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 7/24/2024 |
ALMS Alumis | $9.44
-2.1% | 7/23/2024 | Initiated by | Leerink Partners | - | Outperform | $29.00 | Low | View details for Leerink Partners rating of Alumis (NASDAQ:ALMS) on 7/23/2024 |
CELC Celcuity | $12.76
-0.2% | 7/22/2024 | Initiated by | Leerink Partners | - | Outperform | $29.00 | Low | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 7/22/2024 |
BNTC Benitec Biopharma | $10.09
-5.3% | 7/22/2024 | Initiated by | Leerink Partners | - | Outperform | $13.00 | Low | View details for Leerink Partners rating of Benitec Biopharma (NASDAQ:BNTC) on 7/22/2024 |
LNTH Lantheus | $87.32
+1.0% | 7/11/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $106.00 -> $127.00 | Low | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 7/11/2024 |
EHC Encompass Health | $98.98
+0.1% | 7/10/2024 | Initiated by | Leerink Partners | - | Outperform | $100.00 | Low | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 7/10/2024 |
HLVX HilleVax | $1.82
+1.7% | 7/9/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $28.00 -> $2.00 | Low | View details for Leerink Partners rating of HilleVax (NASDAQ:HLVX) on 7/9/2024 |
What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad) A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation.
In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today. |
RVTY Revvity | $111.11
-0.2% | 7/8/2024 | Initiated by | Leerink Partners | - | Outperform | $125.00 | Low | View details for Leerink Partners rating of Revvity (NYSE:RVTY) on 7/8/2024 |
SDGR Schrödinger | $20.39
+6.4% | 7/2/2024 | Initiated by | Leerink Partners | - | Outperform | $29.00 | Low | View details for Leerink Partners rating of Schrödinger (NASDAQ:SDGR) on 7/2/2024 |
COR Cencora | $245.50
+0.9% | 6/27/2024 | Reiterated by | Leerink Partners | - | Outperform -> Outperform | $275.00 -> $275.00 | Low | View details for Leerink Partners rating of Cencora (NYSE:COR) on 6/27/2024 |
ALNY Alnylam Pharmaceuticals | $247.05
-0.7% | 6/25/2024 | Target Raised by | Leerink Partners | - | Market Perform -> Market Perform | $138.00 -> $159.00 | Low | View details for Leerink Partners rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 6/25/2024 |
SLDB Solid Biosciences | $5.23
+5.4% | 6/24/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $12.00 -> $12.00 | Low | View details for Leerink Partners rating of Solid Biosciences (NASDAQ:SLDB) on 6/24/2024 |
SRPT Sarepta Therapeutics | $110.50
-0.3% | 6/24/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $165.00 -> $230.00 | Low | View details for Leerink Partners rating of Sarepta Therapeutics (NASDAQ:SRPT) on 6/24/2024 |
MREO Mereo BioPharma Group | $3.68
+2.8% | 6/20/2024 | Target Raised by | Leerink Partners | - | Outperform -> Outperform | $6.00 -> $8.00 | Low | View details for Leerink Partners rating of Mereo BioPharma Group (NASDAQ:MREO) on 6/20/2024 |
QTTB Q32 Bio | $27.04
-0.9% | 5/21/2024 | Initiated by | Leerink Partners | - | Outperform | $54.00 | Low | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 5/21/2024 |
BOLT Bolt Biotherapeutics | $0.57
| 5/15/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $3.00 -> $1.00 | Low | View details for Leerink Partners rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/15/2024 |
AIRS AirSculpt Technologies | $6.77
+6.6% | 5/14/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $8.25 -> $5.00 | Low | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2024 |
EHAB Enhabit | $7.41
-0.7% | 5/14/2024 | Upgraded by | Leerink Partners | - | Underperform -> Market Perform | $8.50 | Low | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 5/14/2024 |
AQST Aquestive Therapeutics | $4.56
-3.8% | 5/10/2024 | Initiated by | Leerink Partners | - | Outperform | $8.00 | Low | View details for Leerink Partners rating of Aquestive Therapeutics (NASDAQ:AQST) on 5/10/2024 |
MYGN Myriad Genetics | $15.12
-1.2% | 5/8/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $25.00 -> $35.00 | Low | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 5/8/2024 |
BPMC Blueprint Medicines | $96.66
+2.0% | 5/6/2024 | Upgraded by | Leerink Partners | - | Underperform -> Market Perform | $50.00 -> $97.00 | Low | View details for Leerink Partners rating of Blueprint Medicines (NASDAQ:BPMC) on 5/6/2024 |
CVS CVS Health | $57.07
+0.4% | 5/1/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $87.00 -> $60.00 | Low | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 5/1/2024 |
LXRX Lexicon Pharmaceuticals | $0.78
-3.7% | 4/30/2024 | Initiated by | Leerink Partners | - | Outperform | $5.00 | Low | View details for Leerink Partners rating of Lexicon Pharmaceuticals (NASDAQ:LXRX) on 4/30/2024 |
XOMA XOMA | $30.10
+0.3% | 4/29/2024 | Initiated by | Leerink Partners | - | Outperform | $40.00 | Low | View details for Leerink Partners rating of XOMA (NASDAQ:XOMA) on 4/29/2024 |
NGNE Neurogene | $15.59
+1.7% | 4/29/2024 | Initiated by | Leerink Partners | - | Outperform | $46.00 | Low | View details for Leerink Partners rating of Neurogene (NASDAQ:NGNE) on 4/29/2024 |
IMCR Immunocore | $32.12
-0.9% | 4/29/2024 | Initiated by | Leerink Partners | - | Outperform | $74.00 | Low | View details for Leerink Partners rating of Immunocore (NASDAQ:IMCR) on 4/29/2024 |
CVAC CureVac | $2.56
+2.8% | 4/25/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $12.00 -> $4.00 | Low | View details for Leerink Partners rating of CureVac (NASDAQ:CVAC) on 4/25/2024 |
TNDM Tandem Diabetes Care | $30.74
+2.0% | 4/25/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $34.00 -> $45.00 | Low | View details for Leerink Partners rating of Tandem Diabetes Care (NASDAQ:TNDM) on 4/25/2024 |
RNAC Cartesian Therapeutics | $16.62
-1.9% | 4/23/2024 | Initiated by | Leerink Partners | - | Outperform | $39.00 | Low | View details for Leerink Partners rating of Cartesian Therapeutics (NASDAQ:RNAC) on 4/23/2024 |
ANAB AnaptysBio | $21.24
+4.6% | 4/16/2024 | Initiated by | Leerink Partners | - | Outperform | $47.00 | Low | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/16/2024 |
MNMD Mind Medicine (MindMed) | $7.04
-6.4% | 4/15/2024 | Initiated by | Leerink Partners | - | Outperform | $20.00 | Low | View details for Leerink Partners rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 4/15/2024 |
LENZ LENZ Therapeutics | $34.28
+1.1% | 4/15/2024 | Initiated by | Leerink Partners | - | Outperform | $32.00 | Low | View details for Leerink Partners rating of LENZ Therapeutics (NASDAQ:LENZ) on 4/15/2024 |
ARDX Ardelyx | $5.14
+4.5% | 4/5/2024 | Initiated by | Leerink Partners | - | Outperform | $14.00 | Low | View details for Leerink Partners rating of Ardelyx (NASDAQ:ARDX) on 4/5/2024 |
LRMR Larimar Therapeutics | $6.13
+0.8% | 4/3/2024 | Initiated by | Leerink Partners | - | Outperform | $25.00 | Low | View details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 4/3/2024 |
NUVL Nuvalent | $92.73
+1.7% | 4/1/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $69.00 -> $110.00 | Low | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 4/1/2024 |
SGMT Sagimet Biosciences | $4.50
-0.4% | 3/25/2024 | Initiated by | Leerink Partners | - | Outperform | $26.00 | Low | View details for Leerink Partners rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/25/2024 |
WBA Walgreens Boots Alliance | $8.27
+0.4% | 3/18/2024 | Target Lowered by | Leerink Partners | - | Market Perform -> Market Perform | $23.00 -> $22.00 | Low | View details for Leerink Partners rating of Walgreens Boots Alliance (NASDAQ:WBA) on 3/18/2024 |
MIRM Mirum Pharmaceuticals | $43.48
-0.5% | 3/18/2024 | Target Lowered by | Leerink Partners | - | Outperform -> Outperform | $44.00 -> $43.00 | Low | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 3/18/2024 |
RGLS Regulus Therapeutics | $1.40
| 3/18/2024 | Initiated by | Leerink Partners | - | Outperform | $6.00 | Low | View details for Leerink Partners rating of Regulus Therapeutics (NASDAQ:RGLS) on 3/18/2024 |
SPRB Spruce Biosciences | $0.49
| 3/14/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $9.00 -> $2.00 | Low | View details for Leerink Partners rating of Spruce Biosciences (NASDAQ:SPRB) on 3/14/2024 |
AMLX Amylyx Pharmaceuticals | $5.24
| 3/11/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 3/11/2024 |
RGNX REGENXBIO | $9.18
-4.7% | 3/6/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $37.00 | Low | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 3/6/2024 |
SPRY ARS Pharmaceuticals | $13.42
-1.0% | 3/5/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $6.00 -> $18.00 | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/5/2024 |
KYTX Kyverna Therapeutics | $3.99
-3.2% | 3/4/2024 | Initiated by | Leerink Partners | - | Outperform | $48.00 | Low | View details for Leerink Partners rating of Kyverna Therapeutics (NASDAQ:KYTX) on 3/4/2024 |
WBA Walgreens Boots Alliance | $8.27
+0.4% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $23.00 | Low | View details for Leerink Partners rating of Walgreens Boots Alliance (NASDAQ:WBA) on 2/26/2024 |
XRAY DENTSPLY SIRONA | $18.64
+0.6% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $42.00 | Low | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 2/26/2024 |
RCM R1 RCM | $14.31
| 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $14.00 | Low | View details for Leerink Partners rating of R1 RCM (NASDAQ:RCM) on 2/26/2024 |
PGNY Progyny | $14.97
+7.1% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $49.00 | Low | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 2/26/2024 |
PINC Premier | $22.42
+0.9% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $22.50 | Low | View details for Leerink Partners rating of Premier (NASDAQ:PINC) on 2/26/2024 |
PDCO Patterson Companies | $20.28
+1.1% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $36.00 | Low | View details for Leerink Partners rating of Patterson Companies (NASDAQ:PDCO) on 2/26/2024 |
OMI Owens & Minor | $12.23
+2.9% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $24.00 | Low | View details for Leerink Partners rating of Owens & Minor (NYSE:OMI) on 2/26/2024 |
MCK McKesson | $628.15
+1.1% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $600.00 | Low | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 2/26/2024 |
LH Laboratory Co. of America | $240.42
+1.1% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $260.00 | Low | View details for Leerink Partners rating of Laboratory Co. of America (NYSE:LH) on 2/26/2024 |
IQV IQVIA | $197.57
+1.6% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $290.00 | Low | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 2/26/2024 |
HIMS Hims & Hers Health | $23.94
+9.8% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $10.00 | Low | View details for Leerink Partners rating of Hims & Hers Health (NYSE:HIMS) on 2/26/2024 |
GDRX GoodRx | $4.29
-0.5% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $8.00 | Low | View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 2/26/2024 |
NVST Envista | $21.39
+5.0% | 2/26/2024 | Initiated by | Leerink Partners | - | Underperform | $19.00 | Low | View details for Leerink Partners rating of Envista (NYSE:NVST) on 2/26/2024 |
What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad) A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation.
In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today. |
TDOC Teladoc Health | $10.40
+15.6% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $17.00 | Low | View details for Leerink Partners rating of Teladoc Health (NYSE:TDOC) on 2/26/2024 |
CVS CVS Health | $57.07
+0.4% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $88.00 | Low | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 2/26/2024 |
HSIC Henry Schein | $73.91
+0.2% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $78.00 | Low | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 2/26/2024 |
DGX Quest Diagnostics | $164.19
+1.8% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $135.00 | Low | View details for Leerink Partners rating of Quest Diagnostics (NYSE:DGX) on 2/26/2024 |
DOCS Doximity | $48.00
-3.8% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $32.00 | Low | View details for Leerink Partners rating of Doximity (NASDAQ:DOCS) on 2/26/2024 |
CERT Certara | $9.77
+2.3% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $19.00 | Low | View details for Leerink Partners rating of Certara (NASDAQ:CERT) on 2/26/2024 |
COR Cencora | $245.50
+0.9% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $261.00 | Low | View details for Leerink Partners rating of Cencora (NYSE:COR) on 2/26/2024 |
CAH Cardinal Health | $123.30
+2.5% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $125.00 | Low | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 2/26/2024 |
ALGN Align Technology | $228.39
+2.0% | 2/26/2024 | Initiated by | Leerink Partners | - | Market Perform | $310.00 | Low | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 2/26/2024 |
ACCD Accolade | $3.73
+4.8% | 2/26/2024 | Initiated by | Leerink Partners | - | Outperform | $16.00 | Low | View details for Leerink Partners rating of Accolade (NASDAQ:ACCD) on 2/26/2024 |
APLT Applied Therapeutics | $9.32
-1.2% | 2/22/2024 | Initiated by | Leerink Partners | - | Outperform | $12.00 | Low | View details for Leerink Partners rating of Applied Therapeutics (NASDAQ:APLT) on 2/22/2024 |
RAPT RAPT Therapeutics | $1.04
-3.7% | 2/21/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $42.00 -> $10.00 | Low | View details for Leerink Partners rating of RAPT Therapeutics (NASDAQ:RAPT) on 2/21/2024 |
BTSG BrightSpring Health Services | $18.75
-0.2% | 2/20/2024 | Initiated by | Leerink Partners | - | Outperform | $15.00 | Low | View details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 2/20/2024 |
ENGN enGene | $7.67
+2.3% | 2/20/2024 | Initiated by | Leerink Partners | - | Outperform | $31.00 | Low | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 2/20/2024 |
SYBX Synlogic | $1.41
-2.8% | 2/9/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Synlogic (NASDAQ:SYBX) on 2/9/2024 |
AMGN Amgen | $289.77
+0.7% | 2/7/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $324.00 -> $318.00 | Low | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 2/7/2024 |
UTHR United Therapeutics | $367.36
+0.8% | 2/5/2024 | Initiated by | Leerink Partners | - | Outperform | $330.00 | Low | View details for Leerink Partners rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024 |
TSVT 2seventy bio | $3.16
+1.6% | 1/31/2024 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $5.00 -> $18.00 | Low | View details for Leerink Partners rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024 |
NPCE NeuroPace | $9.00
-2.1% | 1/30/2024 | Initiated by | Leerink Partners | - | Outperform | $22.00 | Low | View details for Leerink Partners rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024 |
IMNM Immunome | $9.51
+1.9% | 1/29/2024 | Initiated by | Leerink Partners | - | Outperform | $30.00 | Low | View details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 1/29/2024 |
PYXS Pyxis Oncology | $2.13
-44.2% | 1/23/2024 | Initiated by | Leerink Partners | - | Outperform | $12.00 | Low | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024 |
AXNX Axonics | $70.98
| 1/12/2024 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $71.00 | Low | View details for Leerink Partners rating of Axonics (NASDAQ:AXNX) on 1/12/2024 |
AGL agilon health | $1.78
+6.6% | 1/8/2024 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of agilon health (NYSE:AGL) on 1/8/2024 |
ALVR AlloVir | $0.58
+1.8% | 12/22/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of AlloVir (NASDAQ:ALVR) on 12/22/2023 |
WVE Wave Life Sciences | $14.35
+0.6% | 12/19/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $5.00 -> $12.00 | Low | View details for Leerink Partners rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023 |
INCY Incyte | $70.45
-0.8% | 12/13/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $78.00 | Low | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 12/13/2023 |
NBTX Nanobiotix | $3.83
-5.9% | 12/8/2023 | Initiated by | Leerink Partners | - | Outperform | $11.00 | Low | View details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023 |
TNYA Tenaya Therapeutics | $2.16
-2.7% | 11/30/2023 | Initiated by | Leerink Partners | - | Outperform | $7.00 | Low | View details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023 |
LXEO Lexeo Therapeutics | $6.20
+1.3% | 11/28/2023 | Initiated by | Leerink Partners | - | Outperform | $19.00 | Low | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023 |
ABVX ABIVAX Société Anonyme | $8.65
-2.4% | 11/14/2023 | Initiated by | Leerink Partners | - | Outperform | $20.00 | Low | View details for Leerink Partners rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023 |
ZNTL Zentalis Pharmaceuticals | $3.18
+1.6% | 11/7/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $15.00 | Low | View details for Leerink Partners rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023 |
TSVT 2seventy bio | $3.16
+1.6% | 10/30/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $6.00 | Low | View details for Leerink Partners rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023 |
BEAM Beam Therapeutics | $23.52
-4.0% | 10/20/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | $75.00 -> $20.00 | Low | View details for Leerink Partners rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023 |
FDMT 4D Molecular Therapeutics | $7.99
-5.0% | 10/18/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $24.00 | Low | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023 |
AXGN AxoGen | $13.10
+1.6% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $9.00 | Low | View details for Leerink Partners rating of AxoGen (NASDAQ:AXGN) on 10/16/2023 |
AXNX Axonics | $70.98
| 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $70.00 | Low | View details for Leerink Partners rating of Axonics (NASDAQ:AXNX) on 10/16/2023 |
PRCT PROCEPT BioRobotics | $94.45
+1.9% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $37.00 | Low | View details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023 |
DXCM DexCom | $74.48
-1.0% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $110.00 | Low | View details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/16/2023 |
EW Edwards Lifesciences | $70.56
+1.5% | 10/16/2023 | Initiated by | Leerink Partners | - | Market Perform | $75.00 | Low | View details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023 |
INSP Inspire Medical Systems | $186.19
+0.8% | 10/16/2023 | Initiated by | Leerink Partners | - | Market Perform | $159.00 | Low | View details for Leerink Partners rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023 |
TNDM Tandem Diabetes Care | $30.74
+2.0% | 10/16/2023 | Initiated by | Leerink Partners | - | Market Perform | $21.00 | Low | View details for Leerink Partners rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023 |
ISRG Intuitive Surgical | $550.43
+1.6% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $342.00 | Low | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/16/2023 |
VCEL Vericel | $56.71
-1.0% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $42.00 | Low | View details for Leerink Partners rating of Vericel (NASDAQ:VCEL) on 10/16/2023 |
PODD Insulet | $262.99
-1.3% | 10/16/2023 | Initiated by | Leerink Partners | - | Outperform | $184.00 | Low | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 10/16/2023 |
AMGN Amgen | $289.77
+0.7% | 10/11/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $267.00 -> $318.00 | Low | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 10/11/2023 |
NBIX Neurocrine Biosciences | $125.00
+1.4% | 10/6/2023 | Target Raised by | Leerink Partners | Analyst M. Goodman | | $125.00 -> $135.00 | Low | View details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 10/6/2023 |
GPCR Structure Therapeutics | $30.10
-8.0% | 9/29/2023 | Target Raised by | Leerink Partners | - | | $46.00 -> $97.00 | Low | View details for Leerink Partners rating of Structure Therapeutics (NASDAQ:GPCR) on 9/29/2023 |
SPRY ARS Pharmaceuticals | $13.42
-1.0% | 9/21/2023 | Downgraded by | Leerink Partners | - | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023 |
PTCT PTC Therapeutics | $42.89
+2.2% | 9/18/2023 | Target Lowered by | Leerink Partners | Analyst J. Schwartz | | $44.00 -> $30.00 | Low | View details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 9/18/2023 |
SPRB Spruce Biosciences | $0.49
| 9/8/2023 | Upgraded by | Leerink Partners | - | Market Perform -> Outperform | $3.00 -> $9.00 | Low | View details for Leerink Partners rating of Spruce Biosciences (NASDAQ:SPRB) on 9/8/2023 |
What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad) A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation.
In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come. Click here now to watch the full briefing and discover the steps to take today. |
DSGN Design Therapeutics | $5.56
+1.5% | 8/15/2023 | Reiterated by | Leerink Partners | - | Outperform -> Market Perform | $6.00 | Low | View details for Leerink Partners rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
CYTK Cytokinetics | $47.67
-4.4% | 8/15/2023 | Initiated by | Leerink Partners | - | Outperform | $58.00 | Low | View details for Leerink Partners rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
EXEL Exelixis | $34.83
+0.5% | 8/8/2023 | Initiated by | Leerink Partners | - | Market Perform | $18.00 | Low | View details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $26.60
+4.2% | 8/8/2023 | Initiated by | Leerink Partners | - | Outperform | $33.00 | Low | View details for Leerink Partners rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
NUVL Nuvalent | $92.73
+1.7% | 8/8/2023 | Initiated by | Leerink Partners | - | Market Perform | $42.00 | Low | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
NVCR NovoCure | $17.09
+1.4% | 8/4/2023 | Initiated by | Leerink Partners | - | Outperform | $51.00 | Low | View details for Leerink Partners rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $82.45
-0.1% | 7/26/2023 | Reiterated by | Leerink Partners | Analyst M. Goodman | Outperform | $25.00 | Low | View details for Leerink Partners rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
NBIX Neurocrine Biosciences | $125.00
+1.4% | 7/24/2023 | Upgraded by | Leerink Partners | Analyst M. Goodman | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX Cryoport | $6.58
+0.2% | 7/13/2023 | Downgraded by | Leerink Partners | Analyst P. Souda | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Cryoport (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol-Myers Squibb | $58.22
+0.6% | 7/10/2023 | Reiterated by | Leerink Partners | Analyst D. Risinger | Market Perform | | Low | View details for Leerink Partners rating of Bristol-Myers Squibb (NYSE:BMY) on 7/10/2023 |
EHAB Enhabit | $7.41
-0.7% | 6/20/2023 | Reiterated by | Leerink Partners | Analyst W. Mayo | Underperform | | Low | View details for Leerink Partners rating of Enhabit (NYSE:EHAB) on 6/20/2023 |
OCS Oculis | $14.75
-1.1% | 6/12/2023 | Reiterated by | Leerink Partners | Analyst M. Goodman | Outperform | | Low | View details for Leerink Partners rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
BPMC Blueprint Medicines | $96.66
+2.0% | 6/5/2023 | Downgraded by | Leerink Partners | Analyst A. Berens | Market Perform -> Underperform | | Low | View details for Leerink Partners rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023 |
ELEV Elevation Oncology | $0.61
+5.2% | 5/30/2023 | Upgraded by | Leerink Partners | Analyst A. Berens | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023 |
BOLT Bolt Biotherapeutics | $0.57
| 5/12/2023 | Upgraded by | Leerink Partners | Analyst D. Graybosch | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/12/2023 |
ARWR Arrowhead Pharmaceuticals | $18.32
-2.1% | 5/12/2023 | Downgraded by | Leerink Partners | Analyst M. Foroohar | Outperform -> Market Perform | | Low | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
DHR Danaher | $234.76
+0.7% | 5/1/2023 | Reiterated by | Leerink Partners | Analyst P. Souda | Outperform | | Low | View details for Leerink Partners rating of Danaher (NYSE:DHR) on 5/1/2023 |
PRTA Prothena | $14.44
+0.3% | 4/24/2023 | Reiterated by | Leerink Partners | Analyst R. Li | Outperform | | Low | View details for Leerink Partners rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
GNFT Genfit | $4.24
-1.6% | 4/14/2023 | Reiterated by | Leerink Partners | Analyst T. Smith | Outperform | | Low | View details for Leerink Partners rating of Genfit (NASDAQ:GNFT) on 4/14/2023 |
CNTB Connect Biopharma | $0.99
-5.7% | 4/12/2023 | Reiterated by | Leerink Partners | Analyst T. Smith | Outperform | | Low | View details for Leerink Partners rating of Connect Biopharma (NASDAQ:CNTB) on 4/12/2023 |
ARWR Arrowhead Pharmaceuticals | $18.32
-2.1% | 4/12/2023 | Upgraded by | Leerink Partners | Analyst M. Foroohar | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $55.91
-0.3% | 4/11/2023 | Reiterated by | Leerink Partners | Analyst R. Ruiz | Market Perform | $25.00 | Low | View details for Leerink Partners rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
ACLX Arcellx | $87.22
| 3/30/2023 | Target Raised by | Leerink Partners | - | Outperform | $35.00 -> $39.00 | Low | View details for Leerink Partners rating of Arcellx (NASDAQ:ACLX) on 3/30/2023 |
ABT Abbott Laboratories | $117.57
+1.4% | 3/31/2023 | Target Raised by | Leerink Partners | - | Market Perform | $90.00 -> $102.00 | Low | View details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 3/31/2023 |
REGN Regeneron Pharmaceuticals | $745.48
+0.3% | 3/27/2023 | Upgraded by | Leerink Partners | Analyst D. Risinger | Market Perform -> Outperform | | Low | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
PTCT PTC Therapeutics | $42.89
+2.2% | 3/17/2023 | Reiterated by | Leerink Partners | Analyst J. Schwartz | Market Perform | $48.00 | Low | View details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
CNTA Centessa Pharmaceuticals | $18.19
+8.7% | 3/17/2023 | Reiterated by | Leerink Partners | Analyst D. Risinger | Outperform | $6.00 | Low | View details for Leerink Partners rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
HALO Halozyme Therapeutics | $45.70
-0.1% | 3/16/2023 | Downgraded by | Leerink Partners | Analyst D. Risinger | Outperform -> Market Perform | $42.00 | Low | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
ARGX argenx | $600.35
+1.4% | 3/3/2023 | Target Raised by | Leerink Partners | - | Outperform | $430.00 -> $435.00 | Low | View details for Leerink Partners rating of argenx (NASDAQ:ARGX) on 3/3/2023 |
GPCR Structure Therapeutics | $30.10
-8.0% | 2/28/2023 | Reiterated by | Leerink Partners | Analyst D. Risinger | Outperform | | Low | View details for Leerink Partners rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
CGEN Compugen | $1.45
+1.4% | 2/28/2023 | Reiterated by | Leerink Partners | Analyst D. Graybosch | Outperform | | Low | View details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 2/28/2023 |
IRON Disc Medicine | $63.51
+1.5% | 2/28/2023 | Reiterated by | Leerink Partners | Analyst T. Smith | Outperform | $36.00 | Low | View details for Leerink Partners rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
XNCR Xencor | $24.10
+1.6% | 2/23/2023 | Reiterated by | Leerink Partners | Analyst J. Chang | Outperform | | Low | View details for Leerink Partners rating of Xencor (NASDAQ:XNCR) on 2/23/2023 |
MRNA Moderna | $38.40
+4.0% | 2/24/2023 | Downgraded by | Leerink Partners | Analyst M. Foroohar | Market Perform -> Underperform | $111.00 -> $93.00 | Low | View details for Leerink Partners rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
NKTR Nektar Therapeutics | $1.01
+1.0% | 2/24/2023 | Target Lowered by | Leerink Partners | - | Market Perform | $5.00 -> $3.00 | N/A | View details for Leerink Partners rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
BPMC Blueprint Medicines | $96.66
+2.0% | 2/24/2023 | Target Lowered by | Leerink Partners | - | Market Perform | $45.00 -> $38.00 | Low | View details for Leerink Partners rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $33.83
-4.4% | 2/23/2023 | Target Lowered by | Leerink Partners | - | Market Perform | $34.00 -> $27.00 | Low | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $10.40
+15.6% | 2/23/2023 | Upgraded by | Leerink Partners | Analyst S. Davis | Market Perform -> Outperform | $34.00 | Low | View details for Leerink Partners rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $172.18
+2.6% | 2/10/2023 | Upgraded by | Leerink Partners | Analyst D. Risinger | Underperform -> Market Perform | $135.00 -> $153.00 | Low | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
ENTA Enanta Pharmaceuticals | $9.35
+3.0% | 2/9/2023 | Reiterated by | Leerink Partners | - | Market Perform | $49.00 | Low | View details for Leerink Partners rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 2/9/2023 |
CNTB Connect Biopharma | $0.99
-5.7% | 2/8/2023 | Target Lowered by | Leerink Partners | - | Outperform | $9.00 -> $7.00 | Low | View details for Leerink Partners rating of Connect Biopharma (NASDAQ:CNTB) on 2/8/2023 |
EQ Equillium | $0.73
+1.4% | 2/8/2023 | Target Lowered by | Leerink Partners | - | Outperform | $12.00 -> $7.00 | Low | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 2/8/2023 |
CI The Cigna Group | $330.71
+2.3% | 2/8/2023 | Target Raised by | Leerink Partners | - | Market Perform | $309.00 -> $335.00 | Low | View details for Leerink Partners rating of The Cigna Group (NYSE:CI) on 2/8/2023 |
PINC Premier | $22.42
+0.9% | 2/8/2023 | Target Lowered by | Leerink Partners | - | Outperform | $46.00 -> $42.00 | Low | View details for Leerink Partners rating of Premier (NASDAQ:PINC) on 2/8/2023 |
ILMN Illumina | $137.09
+4.1% | 2/8/2023 | Target Raised by | Leerink Partners | Analyst P. Souda | Outperform | $249.00 -> $250.00 | Low | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 2/8/2023 |
VRTX Vertex Pharmaceuticals | $449.32
-0.4% | 2/8/2023 | Target Lowered by | Leerink Partners | - | Outperform | $374.00 -> $365.00 | Low | View details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
INCY Incyte | $70.45
-0.8% | 2/8/2023 | Reiterated by | Leerink Partners | - | Underperform | $63.00 | Low | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 2/8/2023 |
GMAB Genmab A/S | $20.47
+0.1% | 2/6/2023 | Target Raised by | Leerink Partners | - | Market Perform | $33.00 -> $36.00 | Low | View details for Leerink Partners rating of Genmab A/S (NASDAQ:GMAB) on 2/6/2023 |
FDMT 4D Molecular Therapeutics | $7.99
-5.0% | 2/6/2023 | Target Lowered by | Leerink Partners | Analyst M. Foroohar | Market Perform | $15.00 -> $14.00 | Low | View details for Leerink Partners rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 2/6/2023 |
IMVT Immunovant | $26.54
+1.4% | 2/6/2023 | Target Raised by | Leerink Partners | - | Outperform | $14.00 -> $21.00 | Low | View details for Leerink Partners rating of Immunovant (NASDAQ:IMVT) on 2/6/2023 |
REGN Regeneron Pharmaceuticals | $745.48
+0.3% | 2/6/2023 | Target Raised by | Leerink Partners | Analyst D. Risinger | Market Perform | $770.00 -> $834.00 | Low | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/6/2023 |
GILD Gilead Sciences | $89.84
+1.4% | 2/3/2023 | Target Raised by | Leerink Partners | Analyst D. Risinger | Market Perform | $81.00 -> $91.00 | Low | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 2/3/2023 |
TECH Bio-Techne | $71.19
+3.6% | 2/3/2023 | Target Lowered by | Leerink Partners | - | Outperform | $125.00 -> $110.00 | Low | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 2/3/2023 |
BMRN BioMarin Pharmaceutical | $63.44
+1.4% | 2/3/2023 | Target Raised by | Leerink Partners | - | Outperform | $122.00 -> $130.00 | Low | View details for Leerink Partners rating of BioMarin Pharmaceutical (NASDAQ:BMRN) on 2/3/2023 |
IONS Ionis Pharmaceuticals | $33.83
-4.4% | 2/3/2023 | Target Raised by | Leerink Partners | - | Market Perform | $33.00 -> $34.00 | Low | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/3/2023 |
MRK Merck & Co., Inc. | $100.41
+3.0% | 2/3/2023 | Target Raised by | Leerink Partners | - | Outperform | $120.00 -> $122.00 | Low | View details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 2/3/2023 |
KALV KalVista Pharmaceuticals | $9.28
+3.5% | 2/3/2023 | Target Lowered by | Leerink Partners | - | Outperform | $30.00 -> $20.00 | Low | View details for Leerink Partners rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 2/3/2023 |
TMO Thermo Fisher Scientific | $515.26
+0.5% | 2/2/2023 | Target Raised by | Leerink Partners | - | Outperform | $620.00 -> $630.00 | Low | View details for Leerink Partners rating of Thermo Fisher Scientific (NYSE:TMO) on 2/2/2023 |
HOLX Hologic | $78.68
+0.8% | 2/2/2023 | Target Raised by | Leerink Partners | - | Outperform | $90.00 -> $93.00 | Low | View details for Leerink Partners rating of Hologic (NASDAQ:HOLX) on 2/2/2023 |
AMGN Amgen | $289.77
+0.7% | 2/2/2023 | Target Lowered by | Leerink Partners | - | Market Perform | $282.00 -> $267.00 | Low | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
